PT  - JOURNAL ARTICLE
AU  - Konig, Maximilian F.
AU  - Powell, Mike
AU  - Staedtke, Verena
AU  - Bai, Ren-Yuan
AU  - Thomas, David L.
AU  - Fischer, Nicole
AU  - Huq, Sakibul
AU  - Khalafallah, Adham M.
AU  - Koenecke, Allison
AU  - Papadopoulos, Nickolas
AU  - Kinzler, Kenneth W.
AU  - Vogelstein, Bert
AU  - Vogelstein, Joshua T.
AU  - Athey, Susan
AU  - Zhou, Shibin
AU  - Bettegowda, Chetan
TI  - Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome
AID  - 10.1101/2020.04.02.20051565
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.02.20051565
4099  - http://medrxiv.org/content/early/2020/04/08/2020.04.02.20051565.short
4100  - http://medrxiv.org/content/early/2020/04/08/2020.04.02.20051565.full
AB  - The mortality of Coronavirus disease 2019 (COVID-19) appears to be driven by acute respiratory distress syndrome (ARDS) and a dysregulated immune response to SARS-CoV-2. Emerging evidence suggests that a subset of COVID-19 is characterized by the development of a cytokine storm syndrome (CSS), and interleukin (IL)-6 levels are predictors of COVID-19 severity and in-hospital mortality. Targeting hyper-inflammation in COVID-19 may be critical for reducing mortality.Catecholamines enhance inflammatory injury by augmenting the production of IL-6 and other cytokines through a self-amplifying feed-forward loop in immune cells that requires alpha-1 adrenergic receptor (α1-AR) signaling. Prophylactic inhibition of catecholamine synthesis with the α1-AR antagonist prazosin reduced catecholamines and cytokine responses in mice, and resulted in markedly increased survival following various hyper-inflammatory stimuli. These findings offer a rationale for studying α1-AR antagonists in the prophylaxis of patients with COVID-19-CSS and ARDS.As high infection rates threaten to overwhelm hospital capacity during this pandemic, preventative approaches that ameliorate COVID-19 severity and reduce excessive mortality are desperately needed. We hypothesize that treatment with prazosin of individuals who test positive for SARS-CoV-2 could reduce catecholamine surges, secondary cytokine dysregulation, and mortality.To investigate a potential role for α1-AR antagonists in preventing poor outcomes in ARDS, we conducted a retrospective analysis of hospitalized patients diagnosed with ARDS. Using data from the Truven Health MarketScan Research Database (2010-2017), we identified 12,673 men (age 45-64) with ARDS, of whom 1,189 patients (9.4%) were prescribed α1-AR antagonists in the previous year. Applying logistic regression models, we found that patients with prior use of α1-AR antagonists had lower odds of the composite of need for invasive mechanical ventilation and mortality compared to non-users (AOR 0.80, 95% CI 0.69-0.94, p=0.008). Mirroring findings from pre-clinical models, these data support a clinical rationale to study α1-AR antagonists in the prophylaxis of ARDS and states of local and systemic immune dysregulation.Prospective, randomized clinical trials of alpha-1 receptor antagonists (e.g. prazosin) administered prior to the onset of severe symptoms are needed to assess their efficacy in preventing CSS and reducing mortality in COVID-19.Competing Interest StatementDrs. Staedtke, Bai, Papadopoulos, Kinzler, Vogelstein, and Zhou are inventors on a patent application filed by Johns Hopkins University entitled “Preventing cytokine release syndrome”. Biomed Valley Discoveries has previously funded the work described in Staedke et al. and has licensed related patents from Johns Hopkins University. Drs. Papadopoulos, Kinzler, Vogelstein, and Zhou are entitled to a share of royalties received by the University from Biomed Valley Discoveries. The terms of these arrangements are managed by Johns Hopkins University in accordance with its conflict of interest policies. Dr. Bettegowda reports personal fees from Depuy-Synthes and Bionaut Pharmaceuticals outside the submitted work.Funding StatementDr. Konig was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award no. T32AR048522. This work was further supported by The Virginia and D.K. Ludwig Fund for Cancer Research, The Lustgarten Foundation for Pancreatic Cancer Research, and the BKI Cancer Genetics and Genomics Research Program.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA